Rasagiline: Time to onset of antiparkinson effect is similar when used as a monotherapy or adjunct treatment

Neurologist

Volumn 17, Issue 6, 2011, Pages 318-324

  Wilson, Ronald E ^a   Seeberger, Lauren C ^b   Silver, Dee ^c   Griffith, Alida ^d   Conner, Jill B ^e   Salzman, Phyllis M ^e  

^a Brentwood Medical Center   (United States)

^b Idaho Elks Rehabilitation Hospital   (United States)

^c Coastal Neurology Medical Group ^*  (United States)

^d Booth Gardner Parkinson's Care Center   (United States)

^e Teva Neuroscience   (United States)

Author keywords

bradykinesia; MAO B inhibitor; Parkinson's disease; rasagiline

Indexed keywords

ACETYLSALICYLIC ACID; AMANTADINE; ANTIDEPRESSANT AGENT; ATORVASTATIN; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; ESCITALOPRAM; LEVODOPA; MULTIVITAMIN; RASAGILINE; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ARTHRALGIA; ARTICLE; BRADYKINESIA; CELLULITIS; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DISEASE SEVERITY; DIZZINESS; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG LABELING; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; DRUG WITHDRAWAL; DYSKINESIA; DYSTONIA; FALLING; FEMALE; FOOD AND DRUG ADMINISTRATION; HEADACHE; HIP FRACTURE; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MUSCLE SPASM; NAUSEA; PARKINSON DISEASE; PATIENT MONITORING; PHYSICIAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEPSIS; SIDE EFFECT; THORAX PAIN; TREATMENT DURATION; TREMOR; URINARY TRACT INFECTION; URINE RETENTION; VIRAL UPPER RESPIRATORY TRACT INFECTION; XEROSTOMIA;

ADULT; AGED; AGED, 80 AND OVER; ANTIPARKINSON AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPOKINESIA; INDANS; MALE; MIDDLE AGED; MONOAMINE OXIDASE INHIBITORS; PARKINSON DISEASE; PROSPECTIVE STUDIES; TIME FACTORS;

EID: 80455150083     PISSN: 10747931     EISSN: None     Source Type: Journal    
DOI: 10.1097/NRL.0b013e31822f6872     Document Type: Article

References (32)

1. Lang AE, Lozano AM. Parkinson's disease: First of two parts. N Engl J Med. 1998;339:1044-1053.
2. Poewe W. Treatments for Parkinson disease: Past achievements and current clinical needs. Neurology. 2009;72(7 suppl):S65-S73.
3. Lang AE, Lozano AM. Parkinson's disease: Second of two parts. N Engl J Med. 1998;339:1130-1143.
4. Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease (2001): Treatment guidelines. Neurology. 2001;56(11 suppl 5):S1-S88.
5. Pahwa R, Factor SA, Lyons KE, et al. Practice Parameter: Treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006;66:983-995.
6. Azilect (rasagiline mesylate) prescribing information retrieved from http://www.azilect.com/Resources/PDFs/PrescribingInformationpdf. aspx. TEVA Neuroscience, Inc., Kansa city, MO.
7. Foley P, Gerlach M, Youdim MB, et al. MAO-B inhibitors: Multiple roles in the therapy of neurodegenerative disorders? Parkinsonism Relat Disord. 2000;6:25-47.
8. LeWitt PA. A perspective on adjunctive therapy for Parkinson disease with monoamine oxidase-B inhibition. Clin Neuropharmacol. 2007;30:305-307.
9. Youdim MB, Edmondson D, Tipton KF. The therapeutic potential of monoamine oxidase inhibitors. Nat Rev Neurosci. 2006;7:295-309.
10. Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: The TEMPO Study. Arch Neurol. 2002;59: 1937-1943.
11. Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol. 2004;61:561-566.
12. Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: The PRESTO study. Arch Neurol. 2005;62:241-248.
13. Rascol O, Brooks DJ, Melamed E, et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): A randomised, double-blind, parallel-group trial. Lancet. 2005;365:947-954.
14. Olanow CW, Rascol O, Hauser R, et al. A double-blind, delayedstart trial of rasagiline in Parkinson's disease. N Engl J Med. 2009;361:1268-1278.
15. Hauser RA, Lew MF, Hurtig HI, et al. Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease. Mov Disord. 2009;24:564-573.
16. Rabey JM, Sagi I, Huberman M, et al. Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: A double-blind study as adjunctive therapy to levodopa. Clin Neuropharmacol. 2000;23:324-330.
17. Finberg JP, Lamensdorf I, Weinstock M, et al. Pharmacology of rasagiline (N-propargyl-1R-aminoindan). Adv Neurol. 1999;80: 495-499.
18. Siderowf A, Stern M. Clinical trials with rasagiline: Evidence for short-term and long-term effects. Neurology. 2006;66(10 suppl 4):S80-S88.
19. Chen JJ, Swope DM. Clinical pharmacology of rasagiline: A novel, second-generation propargylamine for the treatment of Parkinson disease. J Clin Pharmacol. 2005;45:878-894.
20. Thebault JJ, Guillaume M, Sevy R. Tolerability, safety, pharmacodynamics, and pharmacokinetics of rasagiline: A potent, selective, and irreversible monoamine oxidase type B inhibitor. Pharmacotherapy. 2004;24:1295-1305.
21. Chen JJ, Swope DM, Dashtipour K. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease. Clin Ther. 2007;29: 1825-1849.
22. LeWitt PA. MAO-B inhibitor know-how: Back to the pharm. Neurology. 2009;72:1352-1357.
23. Freedman NM, Mishani E, Krausz Y, et al. In vivo measurement of brain monoamine oxidase B occupancy by rasagiline, using (11)C-l-deprenyl and PET. J Nucl Med. 2005;46: 1618-1624.
24. Reichmann H, Jost WH. Efficacy and tolerability of rasagiline in daily clinical use: A post-marketing observational study in patients with Parkinson's disease. Eur J Neurol. 2010;17:1164-1171.
25. Cipriani A, Barbui C, Geddes JR. Is the onset of action of antidepressants truly delayed? (Letter). Br Med J Clinical Evidence. At: Http://clinicalevidence.bmj.com/downloads/16-07-07.pdf. Accessed 01/04/11.
26. Harris Interactive. The impact of Parkinson's disease on quality of life. At: Http://www.mdvu.org/emove/article.asp?ID = 610. Updated 12-25-2009. Accessed 01/-04/11.
27. Politis M, Wu K, Molloy S, et al. Parkinson's disease symptoms: The patient's perspective. Mov Disord. 2010;25:1646-1651.
28. Metman LV, Myre B, Verwey N, et al. Test-retest reliability of UPDRS-III, dyskinesia scales, and timed motor tests in patients with advanced Parkinson's disease: An argument against multiple baseline assessments. Mov Disord. 2004;19: 1079-1084.
29. Hobson DE, Lang AE, Martin WR, et al. Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: A survey by the Canadian Movement Disorders Group. JAMA. 2002; 287:455-463.
30. Wilkinson DG, Passmore AP, Bullock R, et al. A multinational, randomised, 12-week, comparative study of donepezil and rivastigmine in patients with mild to moderate Alzheimer's disease. Int J Clin Pract. 2002;56:441-446.
31. Goetz CG, Wuu J, McDermott MP, et al. Placebo response in Parkinson's disease: Comparisons among 11 trials covering medical and surgical interventions. Mov Disord. 2008;23: 690-699.
32. Buck PO, Wilson RE, Seeberger LC, et al. Examination of the UPDRS Bradykinesia Subscale: Equivalence, reliability and validity. Manuscript under editorial review, 2011.